Capital Fund Management S.A. Raises Holdings in Hologic, Inc. (NASDAQ:HOLX)

Capital Fund Management S.A. lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 77.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,376 shares of the medical equipment provider’s stock after buying an additional 69,187 shares during the quarter. Capital Fund Management S.A. owned 0.07% of Hologic worth $11,417,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. General Partner Inc. purchased a new stake in shares of Hologic during the 4th quarter worth $26,000. Venturi Wealth Management LLC lifted its stake in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the period. Finally, Smithfield Trust Co increased its holdings in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 400 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on HOLX shares. Raymond James restated an “outperform” rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Citigroup cut their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Finally, William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $84.62.

Hologic Stock Performance

Hologic stock opened at $57.85 on Friday. The stock has a fifty day moving average price of $62.47 and a 200 day moving average price of $71.55. Hologic, Inc. has a 52 week low of $56.27 and a 52 week high of $84.67. The firm has a market capitalization of $12.98 billion, a P/E ratio of 18.25, a PEG ratio of 2.14 and a beta of 0.82. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.